Abstract
AbstractThe gastrointestinal (GI) tract is one of the systems most commonly affected by transplant complications. It is due to the high vulnerability of the gut mucosa composed of dividing cells, which are susceptible to chemotherapy-induced damage, rich vasculature, constant contact with intestinal microflora, and high content of immune-competent cells.
Publisher
Springer International Publishing
Reference6 articles.
1. Ferrara JL, Harris AC, Greenson JK, et al. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood. 2011;118:6702–8.
2. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21:389–401.
3. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. 2009 (v4.03: June 14, 2010). https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
4. NCCN clinical practice guidelines in oncology (NCCN guidelines). Antiemesis. Version 2.2017. 2017. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf
5. Robak K, Zambonelli J, Bilinski J, Basak GW. Diarrhea after allogeneic stem cell transplantation: beyond graft-versus-host disease. Eur J Gastroenterol Hepatol. 2017;29:495–502.